XBiotech Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sushma Shivaswamy
- Full Time Employees
- 92
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5217 Winnebago Lane Austin TX United States of America 78744
- IPO Date
- Apr 15, 2015
- CIK
- 0001626878
- Website
- xbiotech.com
- Similar Companies
- Business
- XBiotech Inc. (Nasdaq:XBIT), a clinical-stage biopharmaceutical company founded in 2005 and headquartered in Austin, Texas, discovers, develops and commercializes True Human monoclonal antibodies derived from natural human immunity for treating inflammatory diseases, infectious diseases and oncology indications; its lead product candidate Natrunix, a True Human antibody targeting interleukin-1 alpha (IL-1α), is advancing in a Phase II portion of the TASKIN study combined with trifluridine/tipiracil for advanced colorectal cancer; the company is also developing therapies such as bermekimab for inflammatory conditions including cancer and an Unmetix cocktail for shingles. XBiotech operates a fully integrated research, development and manufacturing facility in Austin with a separate infectious disease laboratory; it previously maintained a German subsidiary, XBiotech Germany GmbH, which was dissolved in February 2023; the company targets unmet medical needs in areas such as rheumatology, cardiovascular disease, stroke, heart attack, arthritis and tissue breakdown mediated by IL-1α. In November 2024, XBiotech completed non-clinical data for its novel shingles therapy Unmetix and prepared an Investigational New Drug application submission; in October 2024, it reported ongoing enrollment in the Phase II TASKIN trial for Natrunix; in September 2024, the company successfully completed a U.S. FDA GLP inspection at its facilities.
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB)
Head-To-Head Comparison: XBiotech (NASDAQ:XBIT) and Psyence Biomedical (NASDAQ:PBM)
XBiotech (NASDAQ:XBIT) Share Price Crosses Above Fifty Day Moving Average – Should You Sell?
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm